Loading...
•
Mar 31, 2020
Teva Q1 2020 Earnings Report
Reported strong results driven by increased demand for generics, OTC, and respiratory products, along with operating and net profit growth, contributing to strong free cash flow and reduced net debt.
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported strong first quarter 2020 results, with revenues of $4.4 billion, GAAP diluted EPS of $0.06, non-GAAP diluted EPS of $0.76, and free cash flow of $551 million. The company reaffirmed its full-year 2020 business outlook.
Revenues increased by 5% due to higher generics and OTC sales in Europe, AUSTEDO and Anda in North America, and growth in International Markets.
GAAP gross profit increased by 11% to $2,063 million, with a gross profit margin of 47.3%.
Non-GAAP operating income increased by 22% to $1,244 million.
Free cash flow was $551 million, driven by higher operating profit and significant consumption of inventories.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comOther Activities Revenue
CapyFin.comRevenue by Geographic Location
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income